Reports Q3 revenue $93.97M, consensus $64.65M. “Our third quarter results reflect another period of strong growth and financial progress,” said Chad Robins, chief executive officer and co-founder of Adaptive Biotechnologies (ADPT). “Our MRD business has reached a major inflection point, having achieved both profitability and cash flow positivity, driven by disciplined execution and accelerating adoption of clonoSEQ. With strong momentum in MRD and good progress in our Immune Medicine programs, we’re well positioned for sustained growth and long-term value creation.”
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ADPT:
- AMD, PLTR, NFLX: Cathie Wood Loads Up on HOOD and Netflix, Sells Advanced Micro and Palantir Stocks
- Adaptive Biotechnologies price target raised to $20 from $15 at Piper Sandler
- DASH, DE, BABA: Cathie Wood Loads Up on DoorDash, Deere & Alibaba, Trims Stakes in ADPT and Others
- Guggenheim starts Adaptive with Buy on cancer test leadership
- Adaptive Biotechnologies initiated with a Buy at Guggenheim